Novel use of leuprorelin acetate in the preventing and treating of osteoporosis

Abstract

The invention discloses the new utilization of Leuprorelin Acetate for preventing senile osteoporosis. Said osteoporosis is a high active derivative of hypothalamus gonadotropin releasing hormone (GnRH). The macro amount of Leuprorelin Acetate can be used to replace waned gonadotrophic hormone function and activates and restores endocrine function for pituitary-ovary or testicle pituitary-sexual gland axis, alleviates ovary or testicle wane, and prevents and treats senile osteoporosis effectively.

Description

technical field [0001] The invention relates to a new application of medicine, in particular to a new pharmaceutical application of leuprorelin acetate. Background technique [0002] Clinically, osteoporosis is a common and easily overlooked metabolic bone disease, which mostly occurs in postmenopausal women and the elderly and is complicated by other diseases (such as diabetes, kidney disease, gastrointestinal tract and ring, bone tumors, etc.) and severe trauma, etc.). A large number of studies have proved that sex hormones play an important role in the dynamic balance between the synthesis of bone tissue and the anti-synthetic activity of adrenaline corticosterone on bone tissue. With the growth of age, the decrease of gonadal function and the decrease of sex hormone level is a very important reason for the formation of osteoporosis. Therefore, clinically, the method of supplementing sex hormones (hormone replacement therapy) is commonly used to prevent and treat osteop...

AI Technical Summary

Problems solved by technology

[0004] Before the present invention, there was no report about the effect of leuprolide acetate on preventing and treating senile osteoporosis